- Home
- SLN vs BWFG Comparison
SLN vs BWFG Comparison
Compare SLN & BWFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- BWFG
- Stock Information
- Founded
- SLN 1994
- BWFG 2002
- Country
- SLN United Kingdom
- BWFG United States
- Employees
- SLN N/A
- BWFG N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- BWFG Major Banks
- Sector
- SLN Health Care
- BWFG Finance
- Exchange
- SLN Nasdaq
- BWFG Nasdaq
- Market Cap
- SLN 273.9M
- BWFG 273.2M
- IPO Year
- SLN N/A
- BWFG N/A
- Fundamental
- Price
- SLN $6.47
- BWFG $37.85
- Analyst Decision
- SLN Buy
- BWFG Buy
- Analyst Count
- SLN 5
- BWFG 2
- Target Price
- SLN $32.60
- BWFG $42.00
- AVG Volume (30 Days)
- SLN 107.6K
- BWFG 20.8K
- Earning Date
- SLN 08-14-2025
- BWFG 07-23-2025
- Dividend Yield
- SLN N/A
- BWFG 2.12%
- EPS Growth
- SLN N/A
- BWFG N/A
- EPS
- SLN N/A
- BWFG 1.62
- Revenue
- SLN $27,701,000.00
- BWFG $69,109,000.00
- Revenue This Year
- SLN N/A
- BWFG $59.47
- Revenue Next Year
- SLN N/A
- BWFG $13.75
- P/E Ratio
- SLN N/A
- BWFG $23.27
- Revenue Growth
- SLN N/A
- BWFG N/A
- 52 Week Low
- SLN $1.97
- BWFG $23.20
- 52 Week High
- SLN $22.47
- BWFG $40.21
- Technical
- Relative Strength Index (RSI)
- SLN 64.49
- BWFG 68.18
- Support Level
- SLN $5.33
- BWFG $37.48
- Resistance Level
- SLN $6.55
- BWFG $38.48
- Average True Range (ATR)
- SLN 0.44
- BWFG 0.85
- MACD
- SLN 0.02
- BWFG 0.14
- Stochastic Oscillator
- SLN 89.34
- BWFG 55.81
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About BWFG Bankwell Financial Group Inc.
Bankwell Financial Group Inc is a bank holding company, engaged in providing financial products and services. It offers products related to commercial lending, retail lending, depository services, and others. The bank's commercial lending products includes owner-occupied commercial real estate loans, commercial real estate investment loans, commercial loans to small and mid-sized businesses and real estate construction and development loans. The retail lending products include residential mortgage loans, home equity lines of credit, and consumer installment loans. Its depository products include checking, savings, money market, certificates of deposit, noninterest-bearing demand, and time deposits.